USPTO serial 79266778
NUMAB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 23, 2021
- Examiner
- KNIGHT, TROY FRANK
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with NUMAB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
CH-8820 Wädenswil, CH
CH
CH
CH-8820 Wädenswil, CH
CH
CH-8820 Wädenswil, CH
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals, biochemicals, biological preparations and enzymes from biotechnological processes for use in industry and science; chemicals, biochemicals, biological preparations and enzymes, antibodies and antibody fragments, from biotechnological processes, for development and manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof; biological products comprising monoclonal antibodies and/or derivatives thereof, namely, antibodies and antibody fragments for use in laboratories, diagnosis and analysis for scientific and research purposes; chemical and biochemical additives, carriers and substances for manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof | ACTIVE | — |
| 005 | Pharmaceutical comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for treatment of cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases and other pathologies, treatable or improvable through use of antibodies that bind to, activate or block the target antigens; medicines comprising monoclonal antibodies and/or derivatives thereof for human medicine for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; medicines comprising monoclonal antibodies and/or derivatives thereof for veterinary use for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; chemical pharmaceutical products comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; diagnostic preparations for medical use comprising monoclonal antibodies and/or derivatives thereof; chemical preparations comprising monoclonal antibodies and/or derivatives thereof for pharmaceutical use for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; chemical preparations for veterinary use comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases | ACTIVE | — |
| 042 | Research and development services in the field of pharmaceutical preparations, biotechnology, antibodies and antibody fragments, proteins, micro-organisms and cells for therapeutic purposes; research services with respect to pharmaceutical preparations, biotechnology, antibody therapy and gene therapy; scientific and technological services of a chemical and molecular biological laboratory; research, product development and quality control services in the field of pharmacy, medical diagnostics and medical therapy; research services in the field of chemistry and biology; industrial analysis and research services in the field of pharmacy, medical diagnosis, and medical therapy; research and development services for antibody products for therapeutic purposes; conducting and preparing chemical, biochemical and biotechnological analysis and research | ACTIVE | — |
| 044 | Medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the fields of immuno-oncology, oncology and immunology; provision of medical information; Medical service featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the nature of preparation and administration of medicines in the field of immuno-oncology, oncology and immunology; advice in connection with dietetics and nutrition; advice with respect to health and provision of health information in the fields of immuno-oncology, oncology and immunology; veterinary services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; hygienic and beauty care for humans and animals; provision of information on diagnostic, prophylactic and therapeutic properties of drugs in the fields of immuno-oncology, oncology and immunology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Numab Therapeutics AG
- Other trademarks owned by Numab Therapeutics AG
- Other trademarks owned by Numab Therapeutics AG
- Other trademarks owned by Numab Therapeutics AG
- Other trademarks owned by Numab Innovation AG
- Other trademarks owned by Numab Therapeutics AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NUMAB
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 23, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Dec 31, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 27, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 13, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 6, 2021 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| May 26, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 26, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 23, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 1, 2021 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Feb 28, 2021 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Feb 23, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 8, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 8, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 6, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 18, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 18, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 18, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 30, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 13, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 13, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 13, 2020 | ALIE | ASSIGNED TO LIE | — |
| Sep 1, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 6, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 14, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 14, 2020 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Feb 13, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 13, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 7, 2020 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Nov 14, 2019 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Oct 19, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 28, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 28, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 18, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 17, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 17, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 13, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 13, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 5, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |